Peter Kojo Quashie

List of Publications by Year
in descending order

34	1,187	566801 15	414034 32
papers	citations	h-index	g-index

39	39	39	1319
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir. Journal of Virology, 2012, 86, 2696-2705.	1.5	212
2	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science, 2021, 374, 423-431.	6.0	144
3	Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology, 2013, 10, 22.	0.9	114
4	The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology, 2014, 11, 7.	0.9	74
5	Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase. Journal of Virology, 2015, 89, 3163-3175.	1.5	66
6	Evolution of HIV integrase resistance mutations. Current Opinion in Infectious Diseases, 2013, 26, 43-49.	1.3	63
7	Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase. Antimicrobial Agents and Chemotherapy, 2013, 57, 6223-6235.	1.4	62
8	Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. Journal of Antimicrobial Chemotherapy, 2014, 69, 2733-2740.	1.3	47
9	Integrase strand transfer inhibitors in the management of HIV-positive individuals. Annals of Medicine, 2014, 46, 123-129.	1.5	43
10	Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 405-411.	1.3	35
11	Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase. Antimicrobial Agents and Chemotherapy, 2016, 60, 600-608.	1.4	33
12	HIV Drug Resistance and the Advent of Integrase Inhibitors. Current Infectious Disease Reports, 2013, 15, 85-100.	1.3	29
13	Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors. Journal of Virology, 2014, 88, 9683-9692.	1.5	22
14	Genetic diversity of SARS-CoV-2 infections in Ghana from 2020-2021. Nature Communications, 2022, 13, 2494.	5.8	22
15	Detection of SARS-CoV-2 intra-host recombination during superinfection with Alpha and Epsilon variants in New York City. Nature Communications, 2022, 13, .	5.8	22
16	Genomic analysis of SARS-CoV-2 reveals local viral evolution in Ghana. Experimental Biology and Medicine, 2021, 246, 960-970.	1.1	20
17	Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. Antiviral Research, 2013, 98, 441-448.	1.9	17
18	Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana. Wellcome Open Research, 0, 6, 173.	0.9	16

#	Article	IF	Citations
19	The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. Aids, 2015, 29, 1459-1466.	1.0	15
20	Recommendations for empowering early career researchers to improve research culture and practice. PLoS Biology, 2022, 20, e3001680.	2.6	15
21	A resveratrol analog termed 3,3â€²,4,4â€²,5,5â€²-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor. Journal of Medical Virology, 2015, 87, 2054-2060.	2.5	14
22	Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor. PLoS ONE, 2015, 10, e0128310.	1.1	14
23	Rapid, Cheap, and Effective COVID-19 Diagnostics for Africa. Diagnostics, 2021, 11, 2105.	1.3	11
24	The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. Journal of the International AIDS Society, 2014, 17, 19518.	1.2	10
25	HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase. Antimicrobial Agents and Chemotherapy, 2014, 58, 7141-7150.	1.4	8
26	Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir. Journal of Antimicrobial Chemotherapy, 2021, 76, 639-647.	1.3	8
27	Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. Journal of Antimicrobial Chemotherapy, 2015, 70, 2810-2815.	1.3	7
28	A SARS-CoV-2 nucleocapsid ELISA represents a low-cost alternative to lateral flow testing for community screening in LMI countries. Journal of Infection, 2022, 84, 48-55.	1.7	7
29	Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. Journal of Virology, 2015, 89, 12002-12013.	1.5	6
30	Subtype-Specific Analysis of the K65R Substitution in HIV-1 That Confers Hypersusceptibility to a Novel Nucleotide-Competing Reverse Transcriptase Inhibitor. Antimicrobial Agents and Chemotherapy, 2015, 59, 3189-3196.	1.4	5
31	HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M. Journal of the International AIDS Society, 2014, 17, 19738.	1.2	4
32	Low COVID-19 impact in Africa: The multifactorial Nexus. AAS Open Research, 0, 4, 47.	1.5	4
33	Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase. Antimicrobial Agents and Chemotherapy, 2014, 58, 3580-3580.	1.4	3
34	Explaining the unexpected COVID-19 trends and potential impact across Africa.. F1000Research, 0, 10, 1177.	0.8	0